Table 1.
Baseline characteristics.
| Vorolanib 100 mg | Vorolanib 150 mg | Vorolanib 200 mg | Total | |
|---|---|---|---|---|
| (n = 4) | (n = 3) | (n = 15) | (n = 22) | |
| Age (years) | 62.8 ± 7.5 | 59.7 ± 6.8 | 51.7 ± 9.5 | 54.8 ± 9.7 |
| Sex | ||||
| Men | 3 (75%) | 2 (67%) | 11 (73%) | 16 (73%) |
| Women | 1 (25%) | 1 (33%) | 4 (27%) | 6 (27%) |
| BMI (kg/m2) | 24.5 ± 2.0 | 22.2 ± 3.5 | 25.3 ± 2.6 | 24.7 ± 2.7 |
| ECOG performance status | ||||
| 0 | 1 (25%) | 0 (0) | 8 (53%) | 9 (41%) |
| 1 | 3 (75%) | 3 (100%) | 7 (47%) | 13 (59%) |
| Prior antitumor therapy | ||||
| Prior nephrectomy | 4 (100%) | 2 (67%) | 15 (100%) | 21 (95%) |
| Prior radiotherapy | 0 | 1 (33%) | 4 (27%) | 5 (23%) |
| Prior chemotherapy | 0 | 0 | 1 (7%) | 1 (5%) |
| Prior targeted therapy | 4 (100%) | 3 (100%) | 14 (93%) | 21 (95%) |